Nasus Pharma Ltd. announced the resignation of Chief Financial Officer Eyal Rubin, effective September 18, 2026, to pursue opportunities outside the life science industry. The departure was not related to any disagreements regarding operations or policies. Oren Elmaliach, currently serving as Director of Finance, has been appointed interim Chief Financial Officer to ensure continuity during the transition period. Nasus Pharma Ltd. is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary powder technology platform.
